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Abstract
Background: HIV/AIDS is associated with a wide range of mucocutaneous disorders some of
which are useful in the clinical staging and prognosis of the syndrome. There is paucity of
information regarding the prevalence and pattern of mucocutaneous disorders among HIV infected
children attending paediatric Care and Treatment Centres (CTC) in Dar es Salaam. Objective To
determine the prevalence and pattern of mucocutaneous disorders among HIV infected children
attending public paediatric 'Care and Treatment Centres' in Dar es Salaam.
Methods:  This was a cross sectional descriptive study involving public paediatric 'Care and
Treatment Centres' in Dar es Salaam. Clinical information was obtained using a questionnaire.
Dermatological examination was carried out in daylight. Investigations were taken as appropriate.
Data was analysed using the Statistical Package for Social Sciences (SPSS) program version 10.0.
Chi-squared and Fisher's exact tests were utilized. A p-value of less than 0.05 was considered
statistically significant.
Results: Three hundred and forty seven HIV infected children (52% males) attending CTCs were
recruited into the study. Mucocutaneous disorders were encountered in 85% of them. There was
no gender difference in the prevalence of the infective mucocutaneous disorders but males had a
higher prevalence of non-infective/inflammatory dermatoses (58%) than females (42%) (p = 0.02).
Overall, mucocutaneous disorders (infective + non infective) were more prevalent in advanced
stages of HIV disease. Children with advanced HIV disease had a significantly increased frequency
of fungal and viral infections (43% and 25% respectively than those with less advanced disease; 24%
and 13% respectively (p = 0.01). Seventy four percent of the HIV-infected children with
mucocutaneous disorders were already on ART.
Conclusion:  Mucocutaneous disorders among HIV infected children attending Care and
Treatment Centres are common and highly variable. Comprehensive management should also
emphasize on the management of mucocutaneous disorders.
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Background
Mucocutaneous disorders are common in both HIV-
infected and non-infected children. Human Immunodefi-
ciency virus infection causes a severe cellular immunode-
ficiency, which results in a greater susceptibility to
infectious, inflammatory and malignant conditions [1].
In early HIV infection, most of the mucocutaneous derm-
atoses are similar to those observed in the non infected
children. With progressive immunosuppression, mucocu-
taneous eruptions, become more common and include
patterns which are atypical, difficult to diagnose and
resistant to treatment [2-4]. Candida albicans infection pre-
senting as extensive oral thrush or recalcitrant monilial
diaper dermatitis is the most common and often the first
manifestation of paediatric HIV infection. Bacterial infec-
tions including severe forms of staphylococcal impetigo,
ecthyma and furuncles are also common [3,4]. Extensive
molluscum contagiosum, Herpes simplex infection and
plane warts are also common with lesions which are more
widely distributed and very difficult to treat [3,4].
Non infective/inflammatory dermatoses like seborrhoeic
eczema and Kaposi's sarcoma, which are common in
adults in whom they become more widespread and refrac-
tory to treatment as CD4+ T-cell count declines, are excep-
tional in children [4-6]. Pruritic Papular Eruption of HIV/
AIDS (PPE) is common in both adults and children with
marked depletion of CD4+ T-lymphocytes [5,7].
In this era of Anti – Retroviral-Therapy (ART), the
immune reconstruction induced by ART would be
expected to significantly reduce the prevalence of many
dermatological diseases as a consequence of a profound
suppression of viral replication with the accompanying
increase in CD4+ T-cell count [1,7].
In Dar es Salaam, there is still paucity of information
regarding the prevalence of mucocutaneous disorders
among HIV infected children attending 'Care and Treat-
ment Centres'. This study was conducted in order to
address this lack of data; the main objective being to
describe the prevalence and pattern of mucocutaneous
disorders in HIV infected children attending these centres
in Dar es Salaam.
Methods
Study design and Setting
This was a descriptive cross-sectional study conducted at
the public Paediatric HIV Care and Treatment Centres in
Dar es Salaam.
Sampling technique
Study subjects were recruited using the 'sampling propor-
tional to size' technique whereby, the number of children
to be included from each CTC depended on the pre-deter-
mined number of children visiting that centre. A sampling
fraction of 24% was used to determine the minimum
number of children from each centre. All HIV infected
children aged up to 17 years, whose parents/guardians
gave informed consent, were enrolled consecutively until
the required sample size was obtained.
Clinical and laboratory work-up
All participants were interviewed to obtain demographic
and clinical information and whether or not they were on
ART. Dermatological examination was done in daylight.
Diagnoses of most dermatoses were done clinically.
Where necessary, appropriate laboratory tests like skin
scrapings, pus swabs and skin biopsies were performed to
confirm the diagnoses. Lymphocyte subsets were deter-
mined using a FACS calibur machine (Becton-Dickinson
USA 2005).
Clinical staging and immunological classification of HIV/
AIDS
Clinical staging was done according to the WHO paediat-
ric staging of HIV/AIDS [8] while immunologic classifica-
tion was done according to the CDC immunologic
classification for HIV infected infants and children [9,10].
Data analysis
Statistical analysis was done using the Statistical Package
for Social Sciences (SPSS) program version 10.0 [11]. Chi-
squared test was used for categorical variables while
Fisher's exact test was used when the number was less than
5. A p-value of less than 0.05 was considered statistically
significant.
Ethical Issues
Ethical clearance was obtained from the Research and
Publications Committee of the Muhimbili University of
Health and Allied Sciences.
Results
Age and sex distribution of HIV-infected children attending 
CTCs
A total of 347 HIV infected children were recruited into
the study (Table 1). Of these, 180 (52%) were males. The
Table 1: Distribution of HIV infected children attending HIV 
CTC by age and sex (n = 347)
Age group (years) Males
n (%)
Females
n (%)
Total
n (%)
0–5 61 (34) 44 (26) 105 (30)
6–10 77 (43) 78 (47) 155 (45)
11–15 36 (20) 39 (23) 75 (22)
16 -≥ 17 6 (3) 6 (4) 12 (3)
Total 180 (52) 167 (48) 347 (100)BMC Public Health 2009, 9:234 http://www.biomedcentral.com/1471-2458/9/234
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age ranged from 6 months to 16 years (mean 7.8 years ±
3.8 SD).
Overall, 85% (294/347) had mucocutaneous disorders.
Eighty seven percent of the males and 83% of the females
had one or more types of mucocutaneous disorders (p =
0.29). Among children aged up to 5 years, 88% had muco-
cutaneous disorders while for those aged 6 years and
above, the prevalence was 83% (p = 0.59).
The pattern of mucocutaneous disorders among HIV 
infected children
A wide range of mucocutaneous disorders was encoun-
tered as shown in table 2. The infectious dermatoses (fun-
gal, viral, bacterial and parasitic infections) accounted for
the majority of the skin diseases (87%) while the inflam-
matory dermatoses (PPE, atopic dermatitis, seborrhoeic
dermatitis and non specific dermatitis) accounted for
69%. Many children had multiple skin conditions and
were therefore counted more than once in certain situa-
tions. When specific mucocutaneous disorders were ana-
lysed, PPE was the commonest condition present in
45.5% followed by superficial fungal infections in 40% of
the children. The most frequent superficial fungal infec-
tion was tinea capitis, occurring in 16% while the least fre-
quent was tinea cruris found in only one child. Viral and
bacterial skin infections were found in 23% and 12%
respectively. Plane warts found in 20%, were the most fre-
quent viral infections while herpes zoster present in 2
patients was the least frequent. The commonest bacterial
skin infection was bullous impetigo in 9.5%. The only
neoplasm encountered was Kaposi's sarcoma present in
one who had been on ART for 1 month. Two children had
nail hyperpigmentation while one child had severe drug
eruption (Stevens-Johnson syndrome) induced by co-tri-
moxazole.
Table 3 shows the distribution of the different types of
mucocutaneous disorders by age-groups. Fungal infec-
tions were more prevalent in the older children aged
above 15 years (58%), while those aged 5 years and below
were the least (20%) affected (p = 0.01). The prevalence of
viral, bacterial, and inflammatory cutaneous disorders did
not show any significant age-group difference (p ≥ 0.25).
The pattern of mucocutaneous disorders by WHO and 
CDC level of immunosuppression
Table 4 shows the prevalence of mucocutaneous disorders
by WHO clinical staging and CDC level of immunosup-
pression. The prevalence of mucocutaneous disorders was
highest in the advanced paediatric WHO stages III (94%)
and IV (100%) and relatively lower in stage II (76%)
while it was lowest (29%) in stage I (p < 0.01). Likewise,
children with severe immunosuppression by CDC criteria
had the highest prevalence of mucocutaneous disorders
(97%), followed by those with moderate immunosup-
pression (84.5%) while children with no evidence of
immunosuppression had the lowest (71%) prevalence (p
< 0.01).
Of the 294 children with mucocutaneous disorders, about
three- quarters (74%) were on ART according to the Tan-
zanian National HIV treatment guidelines. Of these, only
20% had been on ART for a period longer than 12
months. The majority (49%), had been on ART for a
period between six and twelve months while one-third
(31%) had used ART for less than 6 months.
Discussion
From this study, 85% of HIV/AIDS paediatric patients
attending CTCs in Dar es Salaam suffer from a wide range
of mucocutaneous disorders. A high prevalence of skin
diseases among HIV infected children similar to ours has
also been reported by Montri et al in Thailand (83%) [12]
and De Carvalho OV et al in Brazil (82.5%) [13]. Other
studies have reported different prevalence levels [1,14]
indicating a wide regional variation. According to Lumi-
nous LM et al, children less than five years of age, are the
least affected than the older ones [15]. In this study, chil-
dren aged less than 5 years were almost equally affected as
those aged 6 years and above regardless of sex. Siriwan W
Table 2: Mucocutaneous disorders in HIV infected children 
attending Care and Treatment Centres in Dar es Salaam (n= 
294)
Mucocutaneous disorder N %
Non infectious inflammatory dermatoses 202 69
Pruritic papular eruption (PPE) 134 45.5
Atopic dermatitis 31 10.5
Seborrheic dermatitis 24 8
Non specific dermatitis 13 4.4
Infectious dermatoses 256 87
Superficial fungal infections 118 40
Tinea capitis 47 16
Tinea unguim 31 10.5
Tinea corporis 28 9.5
Pityriasis versicolor 11 4
Oral candidosis 11 4
Tinea cruris 1 0.3
Viral infections 68 23
Plane warts 58 20
Molluscun contagiosum 13 4
Herpes simplex 4 1.4
Herpes zoster 2 0.7
Bacterial infections 36 12
Impetigo 28 9.5
Abscess 6 2.0
Cellulitis 3 1.0
Scabies 34 12
Kaposis Sarcoma 1 0.3
Drug reaction 1 0.3
Nail hyperpigmentation 1 0.3BMC Public Health 2009, 9:234 http://www.biomedcentral.com/1471-2458/9/234
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et al reported the prevalence of mucocutaneous disorders
in HIV infected children with severe, moderate and no evi-
dence of immunosuppression as 62%, 43% and 20%
respectively [14]. In this study, the prevalence of mucocu-
taneous disorders among children with severe, moder-
ately severe and no evidence of immunosuppression was
97%, 84.5% and 71% respectively and the differences
were statistically significant. All these studies indicate that
the risk of acquiring mucocutaneous disorders for HIV
infected children rises as the level of immunosuppression
advances.
Infections are the most frequent cause of mucocutaneous
disorders among HIV infected children [1,3,4,14] which
has also been shown in this study. The increased inci-
dence of skin infections is attributed to the depletion of
the Langerhan's cells responsible for the mucocutaneous
immunological system [13]. The distortion of the cutane-
ous immune system is also responsible for the emergence
of a variety of non-infectious inflammatory dermatoses
frequently encountered among HIV/AIDS individuals like
PPE. In this study PPE was present in nearly half (45.5%)
of the affected children.
In our study, Kaposi's sarcoma (KS) was seen in only one
child indicating that this malignancy is rare among HIV
infected children, which is similar to what was reported by
el Hachem M et al [4]. However, other studies have
reported a significant rise in childhood KS among HIV
infected children. Ziegler et al reported that the incidence
of KS had risen more than 40-fold in the era of HIV [16].
Similarly Athale OH et al observed an increased incidence
of KS in HIV infected Zambian children [17]. It is surpris-
ing that, only one child was found to have a drug reaction
(Stevens-Johnson syndrome). This finding probably does
not reflect a true picture and calls for an appropriately
designed follow-up rather than a cross-sectional study in
order to assess the effects of all drugs administered at
CTCs.
Nearly 75% of children with mucocutaneous disorders
were already on ART according to the Tanzanian National
Guidelines on Treatment of HIV/AIDS. The use of ART has
shown a significant reduction in the prevalence of some of
the mucocutaneous disorders in HIV infection as a conse-
quence of an increase in CD4+ T cell lymphocytes [1]. It
was not possible to demonstrate this effect in our study,
because of the study design, which was cross-sectional
rather than follow-up. The apparent high prevalence of
mucocutaneous disorders among these children, who
were already on ART at the time of this study, could be due
to the short ART duration. The majority of these children
(49%) were on ART for six to twelve months, while one-
third had ART for less than six months and only about
Table 3: Distribution of types of mucocutaneous disorders among HIV infected children by age
MUCOCUTANEOUS DISORDER AGE GROUP (years) Total p-value
0–5
n = 105 (%)
6–10
n = 155 (%)
11–15
n = 75
(%)
>15
n = 12 (%)
Inflammatory dermatoses 66 (63) 78 (50) 34 (45) 8 (67) 186 0.71
Fungal infections 21 (20) 60 (39) 30 (40) 7 (58) 118 0.01
Viral infections 15 (14) 28 (14) 22 (29) 3 (25) 68 0.35
Bacterial infection 10 (9.5) 17 (11) 9 (12) 0 (0.0) 36 0.93
Infestation (scabies) 14 (13) 11 (7) 7 (9) 2 (17) 34 0.25
Miscellaneous 1 (1) 0 (0) 2 (3) 0 (0) 3 0.76
Table 4: Prevalence of mucocutaneous disorders among HIV infected children by WHO and CDC disease progression (n = 347)
Mucocutaneous disorders:
Present
n = 294 (%)
Mucocutaneous disorders:
Absent
n = 53 (%)
Total
n = 347 (%)
p-value
WHO paediatric stage
I 2 (29) 5 (71) 7 (2)
II 116 (76) 37 (24) 153 (44) <0.01
III 166 (94) 11 (6) 177 (51)
IV 10 (100) 0 (0) 10 (3)
Immunosuppression level by CDC
No evidence 74 (71) 30 (29) 104 (30)
Moderate 109 (84.5) 20 (15.5) 129 (37) <0.01
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20% had used it for more than one year. For ART to have
a significant effect on mucocutaneous disorders, it needs
to be administered for a longer period of time. In a study
by Donic I. et al, it was found that the use of ART for about
two years reduced significantly the presence of oral candi-
dosis and seborrheic dermatitis [18].
Conclusion
Mucocutaneous disorders among HIV infected children
attending CTCs in Dar es Salaam, regardless of gender or
age-group are common, highly variable and mostly infec-
tive. Their prevalence rises with deteriorating WHO clini-
cal stage as well as CDC level of immunosuppression.
Comprehensive management of HIV infected children
attending CTCs should also emphasize on the manage-
ment of mucocutaneous disorders.
Study limitations
This was a cross-sectional study which could not offer an
opportunity to assess the progress of the pre-existing
mucocutaneous disorders, or document on the newly
evolving lesions while children continued receiving care
from the CTCs
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